Saphtx, Inc. · Newark, New Jersey

Protein therapeutics, translated from the academic lab.

We are a dedicated team of engineers, biologists, and inventors that have a passion for scientific innovation. We engineer protein-based therapeutic strategies for some of the biggest health issues we face. We are at the forefront of translating the innovations and inventions of engineers and scientists in Academia.

HETERO-PEPTIDES BIND ASSEMBLE BIND ASSEMBLE mixed at a chosen molar ratio β-SHEET FIBRIL VIRUS Many binding sites on one fibril = multivalent attachment
The self-assembled peptide platform, drawn from the published description.

Two programs, one platform

Self-assembled peptides, applied twice

Saphtx engineers peptides that do two things at once: one domain binds a target, the other self-assembles into a fibril. The company has aimed that platform at the back of the eye and at SARS-CoV-2.

Neovascular eye disease

SAPHTx is an injectable hydrogel of naturally occurring amino acids, engineered to include an anti-angiogenic peptide, for AMD and diabetic retinopathy.

The ocular program

Antiviral peptides

Peptides designed to bind SARS-CoV-2 specifically and block its entry into human cells, developed under an NSF STTR Phase I award.

The antiviral program

The platform

One peptide, two jobs

The platform is a mixture of hetero-peptides that co-assemble into functionalised β-sheets. One domain binds viral or tissue targets; the other drives assembly into fibrils whose displayed epitope depends on which peptides are mixed in, and in what ratio.

That makes the architecture tunable: the same manufacturing idea can be re-pointed at a different target.

HETERO-PEPTIDES BIND ASSEMBLE BIND ASSEMBLE mixed at a chosen molar ratio β-SHEET FIBRIL VIRUS Many binding sites on one fibril = multivalent attachment
Hetero-peptides, a β-sheet fibril, and multivalent attachment.

Why it matters

What the platform buys

Two domains per peptide

One domain is designed to bind a specific viral protein; the other self-assembles into fibrils. The mix sets the epitope displayed on the surface.

Tunable composition

Fibril binding characteristics are determined by the types of peptides and their molar fractions, so the architecture can be re-pointed at a new target.

Multivalent by design

A fibril presents many binding sites at once, which is how it maintains strong binding to viral protein complexes.

The platform in full

Colourised electron micrograph of SARS-CoV-2 virus particles
SARS-CoV-2 particles. NIAID-RML, CC BY 2.0. Illustration, not company data.

Published

Nature Communications, 2024

“The lasting threat of viral pandemics necessitates the development of tailorable first-response antivirals with specific but adaptive architectures for treatment of novel viral infections. Here, such an antiviral platform has been developed based on a mixture of hetero-peptides self-assembled into functionalized β-sheets capable of specific multivalent binding to viral protein complexes.”

The antiviral program

Work with us

Protein-based therapeutics, translated

Saphtx works with academic inventors to translate engineered proteins toward the clinic. If you would like to work with the company, its inbox is public.